Emerging Insights on Adverse Events During ART and Implications for Treatment: Key Data From Fall 2021

Gregory Huhn, MD, MPHTM:
In this module, we will focus on some of the factors related to current clinical controversies in our decision-making when selecting optimal therapy—particularly first-line therapy—for our patients. These are data from IDWeek in September and the European AIDS Clinical Society (EACS) conference in October of 2021.

We will focus in on 3 areas, starting with weight gain. This topic has dominated conversations among colleagues, but we also should be initiating conversations with our patients regarding the potential for weight gain when starting first-line regimens.

The second topic is metabolic factors and the need to consider potential metabolic complications associated with the antiretroviral therapy (ART) regimens we craft for our patients.

Finally, we will touch on some recent developments in ART exposure in pregnancy, particularly for dolutegravir and for the newest combination licensed this year in the United States: cabotegravir (CAB) and rilpivirine (RPV), the first long-acting regimen now in our armamentarium.

The slide thumbnails in this activity link to a complete PowerPoint slideset that can be found here or downloaded by clicking any of the thumbnails within the activity. 

Clinical Care Options plans to measure the educational impact of this activity, and some questions will be asked twice: once before the discussion that informs the best choice and again after that specific discussion. Your responses will be aggregated for analysis, but your specific responses will not be shared.